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DNA vaccines expressing the envelope (Env) protein of the human immunodeficiency virus have been
relatively ineffective at generating high-titer, long-lasting, neutralizing antibodies in a variety of animal
models. In this study, the murine and human homologues of the complement component, C3d, were used in a
DNA vaccine to enhance the titers of antibody to Env. Initially, plasmids expressing a secreted form of Env
(sgp120) fused to one, two, or three copies of the murine homologue of C3d (mC3d) were constructed. Mice
were inoculated with four vaccinations of DNA or two DNA vaccinations, followed by two boosts of affinity-
purified gp120 protein. Analyses of titers demonstrated that multiple copies of mC3d coupled to sgp120
induced long-lasting, high-titer anti-Env antibody. Priming mice with sgp120-mC3d-DNA, followed by inocu-
lation of purified gp120 protein, elicited the strongest antibody titers; however, the avidity maturation of the
antibody was accelerated in the mice inoculated with sgp120-mC3d3-DNA. In addition, DNAs expressing
sgp120 fused to three copies of the human homologue of C3d (hC3d3) efficiently enhanced the anti-Env
antibody in rabbits. Lastly, antisera from both mice and rabbits vaccinated with DNA expressing sgp120-C3d3
elicited higher titers of neutralizing antibody than did nonfused forms of Env. These results indicate that C3d,
conjugated to sgp120, enhances the antibody responses to Env compared to non-C3d fused forms of Env, and
this approach may be one way to overcome the poor ability of DNA vaccines to generate antibodies to Env.
DNA vaccination (genetic vaccination) induces protective
immunity against a variety of pathogens (for reviews, see ref-
erences 20, 32, 53, and 54). These genetic vaccines consist of
eukaryotic expression plasmids that are inoculated into target
cells and translated into proteins (20). Previous studies have
demonstrated that DNA vaccination effectively induces both
humoral and cellular immune responses to immunogens from
diverse infectious agents (20, 32, 53, 54). However, DNA im-
munizations have been less successful at generating neutraliz-
ing antibodies against human immunodeficiency virus type 1
(HIV-1) (54). Unlike most immunogens, multiple DNA immu-
nizations are required to elicit even modest titers of neutral-
izing antibody to the HIV envelope (Env) glycoprotein (4, 5,
11, 18, 33, 34, 43, 59). In addition, the antibody responses
raised by DNA vaccination, like those to Env (gp120) subunit
immunizations, are transient, rising and falling with each suc-
cessive immunization (26, 42, 51). In HIV-infected patients or
in experimentally SIV-infected rhesus macaques, specific anti-
bodies require 6 to 8 months to achieve affinity maturation and
may be associated with the appearance of neutralizing anti-
body (17). Therefore, we sought to increase the efficacy of
DNA vaccines expressing HIV Env by using a component of
the innate immune system, C3d, in order to enhance antibody
titer, the affinity maturation, and the virus-neutralizing ability
of the elicited antibody.
In the human immune system, C3d is one of the final deg-
radation products of the third complement protein, C3. The
C3d receptor, CD21 or CR2, is located on B cells, follicular
dendritic cells (FDC), and possibly some epithelial tissues (33,
34). One consequence of complement activation is the covalent
attachment of the C3d to antigen. On B lymphocytes, C3d-
CD21 interaction stimulates B cells amplifying lymphocyte ac-
tivation (19). Recently, our laboratory and others have dem-
onstrated that C3d can enhance antibody responses directed
toward a specific antigen encoded by a DNA vaccine (26, 38,
55, 56, 62). A DNA vaccine expressing a fusion of hemagglu-
tinin (HA) from influenza virus or measles virus fused to three
copies of the murine homologue of C3d (mC3d) achieved an
earlier and more efficient immune response (26, 38, 55). These
results demonstrated that mice vaccinated with DNA express-
ing a secreted, soluble HA-mC3d3 immunogen elicited anti-
body that underwent more rapid affinity maturation than an-
tibody generated by non-C3d fused forms of secreted or
transmembrane of HA. This resulted in more rapid appear-
ance of hemagglutination inhibition activity, neutralizing titers,
and protective immunity (26, 38, 55). In addition, our labora-
tory has used a similar approach with the HIV-1 envelope
(gp120) fused at the carboxyl terminus with C3d3 (56). By using
DNA vaccination, BALB/c mice were inoculated and assayed
for enhanced immune responses. The fusion constructs in-
duced higher antibody responses to Env and a faster onset of
affinity maturation than did the respective wild-type gp120
sequences (56).
The present study differs from our past studies in three
significant aspects. (i) In order to determine the number of
C3d genes necessary to elicit the maximum immune response
by DNA vaccination, mice were vaccinated with DNA express-
ing sgp120 fused to one, two, or three copies of mC3d. (ii)
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Even though mice vaccinated with sgp120-mC3d3-DNA elic-
ited enhanced antibody responses, these same antibodies were
unable to neutralize HIV infection. Therefore, in the present
study, vaccination with DNA was followed by protein boosts of
gp120 in order to enhance the neutralizing antibody titers to
Env. (iii) The human homologue of C3d was fused to sgp120
and examined for anti-Env immunogenicity and neutralizing
capability.
MATERIALS AND METHODS
Plasmid DNA. pTR600, a eukaryotic expression vector, has been described
previously (27). Briefly, the vector was constructed to contain the cytomegalo-
virus immediate-early promoter plus intron A for initiating transcription of
eukaryotic inserts and the bovine growth hormone polyadenylation signal for
termination of transcription (Fig. 1). The vector contains the ColE1 origin of
replication for prokaryotic replication and the kanamycin resistance gene for
selection in antibiotic media.
HIV envelope sequences from the isolates, ADA, IIIB, JRFL, and 89.6 en-
coding almost the entire gp120 region (Fig. 1A) and C3d sequences were cloned
into the pTR600 vaccine vector by using unique restriction endonuclease sites
(Fig. 1B). The gp120 segment encodes a region from amino acids 32 to 465 and
ended with the amino acid sequence VAPTRA. The first 32 amino acids were
deleted from the N terminus of each sgp120 and replaced with a leader sequence
from the tissue plasminogen activator (tpA). The vectors expressing sgp120-
mC3d fusion proteins were generated by cloning one, two, or three tandem
repeats of the mouse homologue of C3d in frame with the sgp120 expressing
DNA. The construct design was based upon the method of Dempsey et al. (19).
Linkers composed of two repeats of four glycines and a serine [(G4S)2] were
fused at the junctures of Env and C3d and between each C3d repeat. Potential
proteolytic cleavage sites between the junctions of Env and the junction of C3d3
were mutated by ligating BamHI and BglII restriction endonuclease sites to
mutate an Arg codon to a Gly codon (6). Vectors expressing sgp120-hC3d3 were
generated by cloning three copies of the human homologue of C3d (generously
donated by Adprotech, Saffron-Walden, United Kingdom) in frame with the
sgp120 sequence. Each hC3d gene was optimized to reduce possible recombina-
tion of the tandem C3d genes.
The plasmids were amplified in Escherichia coli DH5; purified by using
endotoxin-free, anion-exchange resin columns (Qiagen, Valencia, Calif.); and
stored at 20°C in distilled H2O. Plasmids were verified by appropriate restric-
tion enzyme digestion and gel electrophoresis. Purity of DNA preparations was
determined based on the optical densities (ODs) at 260 and 280 nm, and there-
fore each DNA vaccine inoculation contained 50 fg/g of DNA/inoculation.
Animals and DNA immunizations. Six- to eight-week-old BALB/c mice (Har-
lan Sprague-Dawley, Indianapolis, Ind.) were used for inoculations. Mice,
housed with free access to food and water, were cared for under U.S. Depart-
ment of Agriculture guidelines for laboratory animals. Mice were anesthetized
with 0.03 to 0.04 ml of a mixture of 5 ml of ketamine HCl (100 mg/ml) and 1 ml
of xylazine (20 mg/ml). Gene gun immunizations were performed on shaved
abdominal skin by using the hand-held Bio-Rad gene delivery system as de-
scribed previously (30, 46, 47). Mice were immunized with two gene gun doses
containing 2 g of DNA per 0.5 mg of approximately 1-m gold beads (Bio-Rad,
Hercules, Calif.) at a helium pressure setting of 400 lb/in2. Six- to eight-week-old
New Zealand White rabbits (Robinson Farms, Clemons, N.C.) were vaccinated
with 250 g of DNA in 0.9% saline by intramuscular injection (125 g/leg).
Purified gp120 (Advanced Biotechnologies, Inc., Columbia, Md.), emulsified in
Freund complete adjuvant (1:1 in saline; Sigma, St. Louis, Mo.), was inoculated
into the leg of each mouse (30 ng) and each rabbit (5 g).
Transfections and expression analysis. The human embryonic kidney cell line,
293T, was transfected (at 5  105 cells/transfection) with 2 g of DNA by using
12% Lipofectamine (Life Technologies, Grand Island, N.Y.) according to the
manufacturer’s guidelines. Supernatants were collected and stored at 20°C.
Cell lysates were collected in 300 l of radioimmunoprecipitation assay lysis
buffer (0.05 M Tris-HCl, pH 8.0; 0.1% sodium dodecyl sulfate [SDS]; 1.0%
Triton X-100; 2 mM phenylmethylsulfonyl fluoride; 0.15 M NaCl) and stored at
20°C. Quantitative antigen capture enzyme-linked immunosorbent assays
(ELISAs) were conducted as previously described (56).
For Western hybridization analysis, 1.5% of supernatant was diluted 1:2 in
SDS sample buffer (Bio-Rad) and loaded onto a 10% polyacrylamide–SDS gel.
The resolved proteins were transferred onto a nitrocellulose membrane (Bio-
Rad) and incubated with a 1:3,000 dilution of polyclonal human HIV-infected
patient antisera in phosphate-buffered saline (PBS) containing 0.05% Tween 20
and 5% fetal calf serum. After an extensive washing, bound human antibodies
were detected by using a 1:5,000 dilution of horseradish peroxidase-conjugated
goat anti-human antiserum and enhanced chemiluminescence (Amersham,
Buckinghamshire, United Kingdom). In order to analyze the presences of anti-
hC3d3 antibodies in sera from vaccinated rabbits, 15 l of sera was incubated for
45 min with 100 l of hC3d3 containing supernatant from 293T cells transfected
with pTR600-tpA-hC3d3. Anti-hC3d3-depleted serum was used to detect hC3d3
or sgp120 proteins by Western blot analysis.
Immunological assays. An endpoint ELISA was performed to assess the titers
of anti-Env immunoglobulin G (IgG) in immune serum by using purified HIV-1
IIIB gp120 Chinese hamster ovary (CHO) cell-expressed protein (Quality Bio-
logicals, Inc., Gaithersburg, Md.) to coat plates as described previously (51).
FIG. 1. Schematic representation of vector DNA vaccine con-
structs. (A) The pTR600 vector contains the cytomegalovirus imme-
diate-early promoter plus intron A for initiating transcription of eu-
karyotic inserts and the bovine growth hormone polyadenylation
terminator (BGH PolyA) for the termination of transcription. The
vector also contains the ColE1 origin of replication for prokaryotic
replication, as well as the kanamycin resistance (Kanr) gene for selec-
tion in antibiotic media. Inserts were cloned into the vector by using
the NheI and BamHI restriction endonuclease sites directly 3 to the
tpA sequence. (B) The first schematic represents the wild-type, trans-
membrane form of the Env protein. The second schematic represents
the secreted gp120 form of the Env. The third schematic represents the
sgp120-C3d1 construct used as a vaccine insert. The fourth schematic
represents the sgp120-C3d2 construct used as a vaccine insert. The fifth
schematic represents the sgp120-C3d3 construct used as a vaccine
insert. Linkers composed of two repeats of four glycines and a serine
[(G4S)2] were fused at the junctures of Env and C3d and between each
C3d repeat.
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Mouse sera from vaccinated mice were allowed to bind and subsequently were
detected by anti-mouse IgG conjugated to horseradish peroxidase. Endpoint
titers were considered positive that were twofold higher than the background
level. Sera that had background titers at the minimum dilution tested were
recorded as less than 1:100 (100).
Avidity ELISAs were performed similarly to serum antibody determination
ELISAs up to the addition of samples and standards (17, 28, 35, 48, 50, 60).
Samples were diluted to give similar concentrations of specific IgG as indicated
by the OD. Plates were washed three times with 0.05% PBS-Tween 20. Different
concentrations of the chaotropic agent, sodium thiocyanate (NaSCN) in PBS,
were then added (0, 1, 1.5, 2, 2.5, and 3 M NaSCN). Plates were allowed to stand
at room temperature for 15 min and then washed six times with PBS-Tween 20.
Subsequent steps were performed similarly to the serum antibody determination
ELISA. The percentage of initial IgG was calculated as a percentage of the initial
OD. All assays were done in triplicate.
Neutralizing antibody assays. Antibody-mediated neutralization of HIV-1
IIIB and 89.6 was measured in an MT-2 cell-killing assay (40). Briefly, cell-free
virus [50 l containing 500 50% tissue culture infective dose(s) of virus] was
added to multiple dilutions of serum samples in 100 l of growth medium in
triplicate wells of 96-well microtiter plates and incubated at 37°C for 1 h before
MT-2 cells were added (5  104 cells in 100 l added per well). Cell densities
were reduced, and the medium was replaced after 3 days of incubation when
necessary. Neutralization was measured by staining viable cells with Finter’s
neutral red when cytopathic effects in control wells were 70% but 100%. The
percentage of protection was determined by calculating the difference in absor-
bance (A540) between test wells (cells plus virus) and dividing this result by the
difference in absorbance between cell control wells (cells only) and virus control
wells (virus only). Neutralizing titers are expressed as the reciprocal of the
plasma dilution required to protect 50% of cells from virus-induced killing. This
50% cutoff corresponds to a 90% reduction in viral antigen synthesis.
Statistics. For statistical analysis of the difference between sgp120 fused to
multiple copies of murine C3d and sgp120 alone or fused to one copy of murine
C3d, the Student t test was used. Differences were considered statistically signif-
icant when P  0.05.
RESULTS
Expression of plasmids. Vaccine plasmids, expressing a se-
creted form of Env (sgp120), were constructed by using the
previously described pTR600 vector (56). The first set of vac-
cine plasmids expressed the sgp120 from the HIV-1 isolate
IIIB (sgp120IIIB) Env or fused to one (sgp120IIIB-mC3d1), two
(sgp120IIIB-mC3d2), or three (sgp120IIIB-mC3d3) copies of
murine C3d (Fig. 1A). The molecularly cloned gp120 region
represented the entire surface domain of Env but excluded the
oligomerization and transmembrane domains and the cyto-
plasmic regions (Fig. 1B). The sgp120IIIB-mC3d fusion pro-
teins were generated by cloning tandem repeats of the mC3d
(19) in frame with the sgp120 gene (Fig. 1B). In addition to the
sgp120IIIB vaccines, env genes were cloned from each of two,
HIV isolates, ADA and 89.6, and these same env genes were
fused to mC3d3.
DNA vaccines efficiently expressed each secreted form of
gp120 and gp120-mC3d3 protein (Fig. 2). However, expression
was lowered by two- to fourfold with plasmids expressing C3d
fused forms of Env as determined by antigen capture ELISA
(data not shown). Human 293T cells were transiently trans-
fected with 2 g of plasmid, and both supernatants and cell
lysates were assayed by ELISA with HIV-Ig. As observed pre-
viously (56), ca. 90% of the Env protein was present in the
supernatant for both sgp120 and sgp120-C3d3-DNA trans-
fected cells.
Western blot analyses revealed sgp120 and sgp120-C3d pro-
teins of the expected sizes (Fig. 2). Using human patient poly-
clonal antisera (HIV-Ig), Western blot analysis showed the
expected broad band of 115 to 120 kDa corresponding to
gp120 (Fig. 2). A higher-molecular-weight band was seen for
each of the sgp120-mC3d fusion proteins (Fig. 2). Consistent
with the antigen capture assay, intense protein bands were
present in the supernatants of cells transfected with sgp120-
DNA. No evidence for the proteolytic cleavage of the sgp120-
C3d fusion protein was seen by Western analysis.
Antibody response to Env gp120 fused with mC3d DNA
immunizations. BALB/c mice were vaccinated by DNA-coated
gold particles via gene gun with a 1-g dose inoculum. Mice
were vaccinated at day 1 and then boosted at week 6. DNA
plasmids expressing sgp120 fused to multiple copies of mC3d
(sgp120IIIB-C3d2 or sgp120IIIB-mC3d3) raised higher titers of
antibody as determined by ELISA than the sgp120IIIB-DNA or
sgp120IIIB-mC3d1-DNA (Fig. 3A). In addition, these mice had
detectable titers of anti-Env antibody after the second inocu-
lation. In vaccinated mice, the temporal pattern for the ap-
pearance of anti-Env antibodies revealed titers that were
boosted after each inoculation with DNA expressing
sgp120IIIB-C3d2 or sgp120IIIB-mC3d3.
At week 12, mice were divided into two groups and vacci-
nated two additional times (weeks 12 and 18). Half of the mice
were inoculated with the same DNA vaccine given at weeks 0
and 6, and the other half were inoculated with 10 g of purified
gp120IIIB protein (Quality Biologicals). Mice primed and
boosted with sgp120IIIB-mC3d3-DNA had an average anti-Env
endpoint titer that peaked at 1:7,000 at week 14. This titer was
maintained for an additional 12 weeks (week 30) after the final
inoculation. In contrast, mice primed with sgp120IIIB-mC3d3-
DNA and boosted with gp120IIIB protein also had an average
peak titer of 1:7,000; however, it took two protein boosts to
achieve this same titer (Fig. 3B). In comparison, slightly higher
titers (1:12,800) were observed in sera from an HIV-infected
patent (HIV-Ig). Interestingly, mice vaccinated with four inoc-
ulations of sgp120IIIB-DNA or sgp120IIIB-mC3d1-DNA had
FIG. 2. Western hybridization to detect expression of vaccine con-
structs in vitro. Human embryonic kidney cells (293T) were transfected
with 2 g of each vaccine plasmid. Supernatant was collected, and
1.5% of total volume was subjected to electrophoresis on a 10% poly-
acrylamide gel. Each blot was probed with HIV-Ig followed by anti-
human IgG conjugated to horseradish peroxidase. Proteins were de-
tected by using a 1:5,000 dilution of horseradish peroxidase-conjugated
goat anti-human antiserum and enhanced chemiluminescence.
(A) Lane 1, molecular mass marker; lane 2, sgp120IIIB-DNA; lane 3,
sgp120IIIB-mC3d1-DNA; lane 4, sgp120IIIB-mC3d2-DNA; lane 5,
sgp120IIIB-mC3d3-DNA. (B) Lane 1, molecular mass marker; lane 2,
sgp120IIIB-DNA; lane 3, sgp120IIIB-mC3d3-DNA; lane 4, sgp120ADA-
DNA; lane 5, sgp120ADA-mC3d3-DNA; lane 6, sgp12089.6-DNA; lane
7, sgp12089.6-mC3d3-DNA.
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little to no increase in anti-Env antibodies over the time pe-
riod. In contrast, mice vaccinated with sgp120IIIB-DNA or
sgp120IIIB-mC3d1-DNA at weeks 0 and 6 and subsequently
boosted with gp120IIIB protein at weeks 12 and 18 had a dra-
matic rise in anti-Env IgG (1:1,000). Non-DNA-primed mice
that were vaccinated with gp120IIIB protein at week 12 showed
no anti-Env antibodies in sera collected at week 14 (data not
shown). These results indicate that mice that were primed with
DNA during the first 12 weeks of vaccination had low antibody
titers to Env but, when these mice were inoculated with puri-
fied gp120IIIB protein, they responded rapidly to vaccination.
The range of anti-Env titers from sera collected at week 20 for
each mouse group supports the conclusion that sgp120 fused to
multiple copies of C3d elicits the highest antibody titers (Fig.
4).
A second set of DNA vaccine plasmids were constructed
(sgp12089.6, sgp12089.6-mC3d3, sgp120ADA, and sgp120ADA-
mC3d3) in order to compare the anti-Env antibody responses
by using env genes from CCR5-utilizing virus isolates (Fig. 3C).
HIV-189.6 is a dualtropic (R5X4) utilizing isolate and HIV-
1ADA is a macrophagetropic (R5) utilizing isolate. Each DNA
plasmid was inoculated into BALB/c mice, and the induction
of anti-Env antibody was compared to antisera from mice
vaccinated with sgp120IIIB-DNA or sgp120IIIB-mC3d3-DNA
(Fig. 3C). All mice vaccinated with any of the sgp120-DNAs
elicited no anti-Env antibody. In addition, mice vaccinated
with DNA expressing the mC3d3 only (tpA-mC3d3-DNA) elic-
ited no anti-Env or anti-mC3d3 antibodies (Fig. 3C and data
not shown). In contrast, mice vaccinated with any of the
sgp120-mC3d3-DNAs had increasing titers of anti-Env anti-
bodies over the 20-week period. All mice had an antibody
response to Env after the second vaccination which peaked at
week 14 and maintained this titer for an additional 16 weeks
(week 30). At week 20, mice vaccinated with sgp120-mC3d3-
DNA had an endpoint dilution titer of 1:5,000 (IIIB), 1:2,000
(ADA), and 1:1,000 (89.6).
Human C3d also enhances anti-Env antibodies. DNA plas-
mids expressing sgp120 fused to three tandem copies of the
human homologue of C3d (hC3d3) were constructed in a sim-
ilar manner as the sgp120-mC3d3 constructs described above.
DNA vaccine plasmids used the env gene from the virus strains
IIIB, 89.6, and JRFL. Each construct efficiently expressed the
sgp120 or sgp120-hC3d3 gene inserts (Fig. 5), and a 250-g
dose of each DNA was inoculated via intramuscular injection
in 0.9% saline into the hind leg of a New Zealand White rabbit
(Robinson Farms, Clemmons, N.C.). Rabbits were chosen to
test sgp120-hC3d3-DNA for enhancement of immune re-
sponses because 81% of the amino acid residues are identical
(90% similar) between human C3d and rabbit C3d. However,
FIG. 3. Anti-Env IgG raised by DNAs expressing sgp120 proteins
in gene gun-vaccinated mice. (A) Mice were primed with DNA at day
0 and boosted at weeks 6, 12, and 18. Sera were obtained from mice at
weeks 0, 6, 8, 12, 14, 18, and 20. Symbols: —, vector; , sgp120IIIB-
DNA; F, sgp120IIIB-mC3d1-DNA; Œ, sgp120IIIB-mC3d2-DNA; ,
sgp120IIIB-mC3d3-DNA. (B) Mice were primed with DNA at day 0 and
6 and then were boosted with sgp120IIIB at weeks 12 and 18. (C) Mice
were primed with DNA at day 0 and boosted at weeks 6, 12, and 18.
Sera were obtained from mice at weeks 0, 6, 8, 12, 14, 18, and 20.
Symbols: —, vector; E, sgp12089.6-DNA; ƒ, sgp120ADA-DNA; ,
sgp120IIIB-DNA; F, sgp12089.6-mC3d3-DNA; , sgp120ADA-mC3d3-
DNA; , sgp120IIIB-mC3d3-DNA; tpA-mC3d3. Sera collected at the
indicated times from each mouse were assayed for specific IgG levels
by ELISA. Then, 96-well plates were coated with recombinant gp120
protein-derived CHO cells expressing the HIV-1 isolate, IIIB. Data are
averages for 5 to 10 mice. Preimmune sera from mice had no detect-
able specific IgG. Endpoint dilution titers were conducted by diluting
the sera until OD values reached background levels. Titers for sera
that had background titers at the minimum dilution tested were less
than 1:100 (100).
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71% of the amino acid residues are identical between human
C3d and mouse C3d. In addition, human C3d bound to CR2 on
the surface of rabbit B cells (Michael Steward [Adprotech],
unpublished data). Therefore, rabbits were vaccinated at day 1
and boosted with the same DNA inoculum at weeks 6, 12, and
18. As seen with sgp120-mC3d fusions, DNA plasmids express-
ing any of the sgp120-hC3d3 raised higher titers of anti-Env
antibody than the sgp120-DNA (Fig. 5). An anti-Env endpoint
dilution titer peaked as high as 1:8,000 (sgp12089.6-hC3d3)
after the fourth vaccination. Rabbits vaccinated with any of
the sgp120-DNA or tpA-hC3d3-DNA elicited little or no anti-
Env antibody. At week 27, all rabbits were vaccinated with 5 g
of affinity-purified gp120IIIB protein. The anti-Env titers in rabbits
inoculated with sgp120JRFL-hC3d3-DNA, sgp12089.6-hC3d3-
DNA, sgp120IIIB-hC3d3-DNA, or sgp12089.6- sgp120IIIB-DNA
increased after protein vaccination (Fig. 5). The fold increase
in elicited antibody between each matched sgp120-DNA and
sgp120-hC3d3-DNA varied between constructs. In our previ-
ous studies, differences in the levels of the antibody raised by
the different Envs appeared to be determined by the specificity
of the raised antibody (56). When antibody was captured on
the homologous Env, all of the C3d fusions appeared to raise
similar levels of antibody. In the present study, antibodies
raised to R5 envelopes (particularly sgp120JR-FL) did not have
as high a titer on ELISA plates coated with purified gp120IIIB
FIG. 4. Individual anti-Env IgG titer raised by DNAs expressing
sgp120 fused to murine C3d. (A) 3. Mice were primed with DNA at
day 0 and boosted at weeks 6, 12, and 18. Sera, collected at week 20,
were assayed by ELISA for specific IgG, and the endpoint dilution titer
was determined. (B) Mice were primed with DNA at days 0 and 6 and
then boosted with sgp120IIIB at weeks 12 and 18. Then, 96-well plates
were coated with recombinant gp120 protein-derived CHO cells ex-
pressing the HIV-1 isolate, IIIB. Each datum point represents the
endpoint dilution titer for an individual mouse. Preimmune sera from
mice had no detectable specific IgG. Endpoint dilution titers were
conducted by diluting the sera until the OD values reached back-
ground levels. The horizontal line in each lane represents the averaged
titer for that group. Other symbols for panels A and B are as defined
in the legend to Fig. 3.
FIG. 5. Anti-Env IgG raised by intramuscular inoculation of DNAs
expressing sgp120 fused to human C3d. Rabbits were primed with
DNA at day 0; boosted at weeks 6, 12, and 18; and boosted with
sgp120IIIB protein at week 27. Sera were obtained from rabbits at
weeks 0, 6, 8, 12, 14, 18, 20, 27, and 29. Symbols: —, vector; ‚,
sgp12089.6-DNA; E, sgp120JRFL-DNA; , sgp120IIIB-DNA; Œ,
sgp12089.6-hC3d3-DNA; F, sgp120JRFL-hC3d3-DNA; , sgp12089.6-
hC3d3-DNA. Sera were collected at the indicated times from each
rabbit and assayed for specific IgG levels by ELISA. Then, 96-well
plates were coated with recombinant gp120 protein-derived CHO cells
expressing the HIV-1 isolate, IIIB. Data are the averages for five
rabbits. Preimmune sera from mice had no detectable specific IgG.
Endpoint dilution titers were conducted by diluting the sera until the
OD values reached background levels. (Inset) Expression of vaccine
constructs in vitro. Human embryonic kidney cells (293T) were trans-
fected with 2 g of each vaccine plasmid. Supernatant was collected,
and 1.5% of total volume was subjected to electrophoresis on a 10%
polyacrylamide gel. Lanes: 1, molecular mass marker; 2, tpA-hC3d3; 3,
sgp120IIIB-DNA; 4, sgp120IIIB-hC3d3-DNA; 5, sgp120JRFL-DNA; 6,
sgp120JRFL-hC3d3-DNA.
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(1:1,000) as titers on plates coated with purified R5 gp120s
(1:3,200). These results demonstrate that the human homo-
logue of C3d, when fused to sgp120, enhances the antibody
titer to Env.
Antisera from rabbits vaccinated with sgp120-hC3d3-DNA
were used to probe for Env and C3d protein. Sera collected at
week 14, 20, and 29 detected hC3d3, sgp120, and sgp120-hC3d3
proteins by Western analysis (Fig. 6A to C). Sera from later
time points produced more intense bands, indicating increas-
ing titers of anti-Env and anti-hC3d3 antibodies with each
successive immunization. In order to determine the specificity
of the rabbit sera for hC3d3, antisera from rabbits vaccinated
with sgp120-hC3d3-DNA were incubated with hC3d3 protein
and then used to probe for proteins via Western analysis (Fig.
6D). Anti-hC3d3-depleted antisera were unable to detect
hC3d3 protein but detected sgp120 Env protein. Therefore,
anti-hC3d3 antibodies are elicited in the rabbit more rapidly
than anti-Env proteins; however, both antigen capture (Fig. 5)
and Western analysis (Fig. 6) indicated that significant levels of
anti-Env antibodies were elicited by DNA vaccination.
Avidity of anti-Env antiserum. Sodium thiocyanate
(NaSCN) displacement ELISAs demonstrated that the avidity
of the antibody generated with sgp120IIIB-mC3d3-expressing
DNA was consistently higher than that from sgp120IIIB-DNA-
vaccinated mice (Fig. 7). Avidity assays were conducted on sera
raised by sgp120IIIB-DNA and sgp120IIIB-mC3d3-DNA be-
cause of the type specificity of the raised antisera and the
commercial availability of the IIIB protein, but not the other
proteins, for use as capture antigen. The avidity of specific
antibodies to Env was compared by using graded concentra-
tions of NaSCN, a chaotropic agent, to disrupt antigen-anti-
body interaction (48). The binding of antibodies with less avid-
ity to the antigen is disrupted at lower concentrations of
NaSCN than that of antibodies with greater avidity to the
antigen. The 50% effective dose of NaSCN antiserum collected
at week 20, after four inoculations of the sgp120IIIB-mC3d3-
DNA vaccine, was 	1.75 M (Fig. 7) and was significantly
higher than for mice vaccinated with sgp120IIIB-mC3d1-DNA
(P  0.05). Mice inoculated with two doses of DNA (weeks 0
and 6) and boosted with Env protein (weeks 12 and 18) had a
less dramatic response than mice inoculated with DNA ex-
pressing C3d-conjugated Env (Fig. 7). The avidity of the anti-
sera from mice vaccinated with sgp120IIIB-DNA was not mea-
sured, since no antibody was elicited (Fig. 3A). Antisera from
mice primed with sgp120IIIB-DNA and boosted with protein
had an ED50 of 	0.5 M. However, mice vaccinated with DNA
expressing sgp120-mC3d3 had an ED50 of 	1.5 M. In addition,
all mice vaccinated with sgp120-mC3d3-DNA had higher
ED50s at week 14 (	1.15 M) compared to mice vaccinated with
sgp120-DNA (	0.5 M). These results indicate that the anti-
body from sgp120IIIB-mC3d3-DNA-vaccinated mice had un-
dergone more-rapid avidity maturation than antibody from
sgp120-DNA-vaccinated mice.
Enhanced induction of neutralizing antibodies. Sera col-
lected at week 20 from vaccinated mice were tested against two
syncytium-inducing viruses, IIIB (X4) and 89.6 (R5X4), for
virus-neutralizing activity. Sera from mice, primed with
sgp120IIIB-mC3d3-DNA and boosted with Env protein, pro-
tected 50% of the MT-2 cells in vitro from HIV-1IIIB infection
FIG. 6. Western blot of anti-hC3d3 antibodies in sera from vacci-
nated rabbit. Human embryonic kidney cells (293T) were transfected
with 2 g of each vaccine plasmid. Supernatant was collected, and
1.5% of the total volume was subjected to electrophoresis on a 10%
polyacrylamide gel. Each blot was probed with antisera from rabbits
vaccinated with sgp12089.6-mC3d3-DNA at the indicated time points.
(A) Week 14 antisera; (B) week 20 antisera; (C) week 29 antisera;
(D) week 29 antisera mixed with 250 g of purified hC3d3 protein.
Lanes: Mock, cell supernatant only; hC3d3, tpA-hC3d3; gp120,
sgp12089.6.
FIG. 7. Avidity of the anti-Env IgG raised by the IIIB Env-DNA
vaccines. Sera were analyzed from week 20 in an Env-specific NaSCN-
displacement ELISA. Plates were coated with recombinant gp120IIIB.
Sera were collected from sgp120IIIB-DNA (), sgp120IIIB-mC3d1-
DNA (E), sgp120IIIB-mC3d2-DNA (), and sgp120IIIB-mC3d3-DNA
(F). Assays used pooled serum samples from each mouse group that
was normalized to the same OD (range, 1:200 to 1:400 for sgp120IIIB
and sgp120IIIB-mC3d1; range, 1:800 to 1:3,200 for sgp120IIIB-mC3d2-
DNA and sgp120IIIB-mC3d3). Data are the averages of three indepen-
dent experiments.
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at a dilution of 1:80 (virus-neutralizing titer) (Table 1). Sera
from mice inoculated with four doses of sgp120IIIB-mC3d3-
DNA elicited a neutralizing titer that protected 50% of the
MT-2 cells from viral infection at a dilution of 1:45. Sera from
mice vaccinated with DNA expressing gp120IIIB only did not
elicit neutralizing antibodies that were detected in this assay
(1:20). In addition, there were no cross-reactive neutralizing
antibodies to HIV-189.6 in the sera from mice vaccinated with
any of the DNAs expressing sgp120 antigens, regardless of
whether they were conjugated to C3d (data not shown).
Similar results were observed with rabbits vaccinated with
DNA expressing C3d-conjugated vaccines. Neutralizing titers
were observed in antisera collected at week 29 from rabbits
primed with gp120IIIB-hC3d3 and boosted with purified
gp120IIIB (1:80). Sera from these rabbits did not protect
MT-2 cells from infection with HIV-189.6 (1:20). Despite
having higher IgG titers than sera collected from mice or
rabbits vaccinated with gp120IIIB-C3d3-DNA, HIV-Ig did not
elicit neutralizing antibodies that were detected in this assay
(1:20).
DISCUSSION
The C3d fragment of the third complement protein (C3) is
one of the final degradation products of the complement sys-
tem pathway (23). In mammalian immune systems, one con-
sequence of complement activation is the covalent attachment
of the C3d to an antigen, leading to the activation of the
immune response (17, 18). In the present study, murine or
human C3d was fused to a soluble form of the surface protein
of the HIV-1 envelope in a DNA vaccine and tested in rodent
systems for enhanced immunogenicity. Mice were vaccinated
with DNA plasmids expressing sgp120 from the strain HIV-
1IIIB fused to different numbers of copies of murine C3d (one,
two, or three copies). Mice vaccinated with DNA expressing
sgp120 fused to multiple copies of C3d had higher titers of
anti-Env antibodies compared to mice vaccinated with
sgp120IIIB-mC3d1-DNA or sgp120-DNA (Fig. 3). Mice vacci-
nated with plasmids expressing sgp120 and C3d3 on separate
plasmids did not elicit detectable anti-Env antibodies after four
inoculations (data not shown). These results are in agreement
those of with Dempsey et al., who originally demonstrated that
C3d must be fused to an antigen in order to elicit the enhanced
immune responses to that antigen (19). Recently, Suradhat et
al. reported that two copies of mC3d fused to bovine rotavirus
(BRV) VP7 or bovine herpesvirus type 1 glycoprotein D did
not enhance antibody titers to either antigen (61). However, in
the present study, two copies of C3d fused to sgp120 elicited
higher anti-Env titers than one copy, and three copies elicited
higher anti-Env titers than two copies (Fig. 3). In addition,
mice given two sgp120IIIB-mC3d2-DNA or sgp120IIIB-mC3d3-
DNA inoculations, followed by two sgp120IIIB protein boosts,
had anti-Env titers similar to those of mice vaccinated with
four DNA inoculations (Fig. 3 and 4). However, in contrast,
mice vaccinated with sgp120IIIB-mC3d1-DNA or sgp120-DNA
elicited little antibody response with four DNA inoculations
but did elicit detectable antibody titers when boosted with
protein. The reason for the lack of an antibody response with
VP7-mC3d2 or glycoprotein D-mC3d2 is unclear; however, the
effectiveness of C3d appears to be antigen dependent. Re-
cently, we have shown that when C3d is coupled to the HA of
influenza virus, which is an immunogenic molecule compared
to Env of HIV-1, the C3d enhancement of anti-HA titers may
not be observed when higher doses of inoculum are adminis-
tered (38, 55). In addition, the route of administration or the
strain of mouse may influence the effectiveness of C3d fusion
immunogens. Intramuscular inoculation of C3d vaccine plas-
mids into BALB/c mice consistently elicited lower titers to the
fused antigen than did intradermal, gene gun inoculation of
plasmids (38, 55). The CD21-mediated enhancement of B-cell
activation is highly dependent on interleukin-4 (IL-4) produc-
tion (39). Previous studies have indicated that IL-4 is enhanced
in mice vaccinated with C3d-conjugated vaccines compared to
non-C3d-fused forms (38, 56). Anti-C3d3 antibodies were ob-
served in rabbits but not in mice. We hypothesize that the
production of anti-hC3d3 antibodies in rabbits is due to the
production of “non-self” hC3d3 proteins in rabbits and, there-
fore, the lack of anti-mC3d3 antibodies is expected in mice.
Further experiments to address anti-hC3d3 antibodies will
have to wait until these vaccines are inoculated into human
populations.
Direct stimulation of B cells, leading to cellular prolifera-
tion, has been proposed as a possible mechanism for C3d-
mediated immune enhancement of antibody responses. The
binding of C3d to CR2 (CD21) on the surface of circulating B
cells has been shown to activate B cells (23). After C3d binds
to the CR2, it cross-links with the signaling receptor, CD19; B
cells then become activated and are directly stimulated to
produce antibody (19, 22, 23). DNA expressing sgp120-mC3d3
is likely to have supported the height of antibody responses by
TABLE 1. Neutralizing antibody titer from vaccinated mice and rabbits
Mouse group Rabbit group
DNA inoculum
(wk 0 and 6)
DNA inoculum
titer
(wk 12 and 18)
gp120IIIB protein
inoculum titer
(wk 12 and 18)
DNA inoculum
(wk 0, 6, 12, and 18)
gp120IIIB protein
inoculum titer
(wk 27)
sgp120IIIB
a NTc 1:20b sgp120IIIB
a 1:20b
sgp120IIIB-mC3d1 1:20 1:27 sgp120IIIB-hC3d3 1:160
sgp120IIIB-mC3d2 1:36 1:33 sgp12089.6 1:20
sgp120IIIB-mC3d3 1:45 1:80 sgp12089.6-hC3d3 1:80
a Sera were tested against each homologous strain, and the titers are shown. Sera tested against the heterologous strain did not show neutralizing titers above
background. The preimmune sera titer has been deducted from each sample.
b Titers are the sample dilution at which 50% of the MT-2 cells were protected from virus-induced killing as measured by neutral red uptake.
c NT, not tested.
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(i) directly stimulating antibody-producing B cells through
CR2 (CD21) and expanding the pool of anti-Env-specific B
cells (22, 23), (ii) the possible lowering by C3d-conjugated
antigen of both the concentration threshold and the affinity
threshold for B-cell activation (14, 39), or (iii) reducing B-cell
apoptosis (7, 31, 52).
CR2 has also been shown to augment antigen presentation
by B cells. A previous study indicated that B cells that express
higher levels of CR2 were more efficient in processing antigen
than those with lower levels of CR2 (10, 52). Significant C3d-
antigen immune complex binding requires a threshold level of
CR2 expression, suggesting that only B cells with the highest
levels of CR2 are likely to participate in the processing and
presentation of antigens. C3d-coupled antigens in our vaccines
may enhance the binding of low-affinity antigens and thereby
enhance antigen presentation to T helper cells. The higher
levels of IL-4 observed in mice vaccinated with C3d3-coupled
antigens may be a reflection of this enhanced presentation
(38). Alternatively, C3d may extend the half-life of the antigen,
allowing for improved presentation to the immune system.
Future studies need to be performed to explore this possibility.
Immunization with DNA expressing sgp120 coupled to mul-
tiple copies of murine C3d resulted in enhanced avidity mat-
uration of anti-Env antibody (Fig. 7). Previous studies have
described the lengthy evolution of antibody responses to HIV
infection (17, 29). Antibodies gradually mature over a period
of months from low avidity to higher avidity levels (17, 29).
Avidity maturation occurs in germinal centers where the so-
matic hypermutation of immunoglobulin results in a large rep-
ertoire of antigen-specific B cells that undergo selection for
high-affinity B-cell receptors. CR2/ mice have impaired hu-
moral immunity, including decreased affinity/avidity matura-
tion and germinal center development (68). C3d may enhance
the avidity of the anti-Env response by binding to CR2 on FDC
and thereby aiding the entry of B cells producing anti-Env
antibody into germinal centers. Prior studies on the avidity of
DNA-raised, anti-Env antibodies have also revealed low-avid-
ity anti-Env antibodies (51). Env is a heavily glycosylated pro-
tein that may allow for it to remain “nonimmunogenic” in
response to immune pressure during chronic HIV infection (6,
8). The formation of germinal centers, which are critical for
antibody maturation, could be impeded by the glycosylation of
Env (36, 63). C3d may help Env overcome this limitation by
directing sgp120-C3d immunogens to FDC and enhancing ger-
minal center formation, leading to enhanced avidity matura-
tion. C3d may also assist in trafficking fused antigens to sites in
the spleen where germinal centers form by binding to CD21 on
FDC. Additional studies will be required to address the mech-
anisms of C3d enhancement and determine whether C3d is
advancing germinal center formation in these vaccinated mice.
In contrast to the enhancement of antibody titers and avidity
maturation of antibodies to Env, neither a DNA prime/DNA
boost or a DNA prime/protein boost strategy with sgp120-C3d
immunogens raised high titers of neutralizing antibody for
HIV-1 Env (Table 1). Mice vaccinated with plasmids express-
ing sgp120-DNA had low levels of neutralizing antibody that
were only modestly increased in mice vaccinated with sgp120-
mC3d3-expressing plasmids. In contrast to other studies (2,
50), priming with DNA followed by gp120 protein boosts did
not increase the titer or breadth of neutralizing antibody.
These differences could be attributed to the form of Env
(monomers versus oligomers) used, the dose of DNA used, or
the animal model (rodents versus primates) used for vaccina-
tion. Previous studies have suggested that oligomeric forms of
Env are superior antigens for raising neutralizing antibody (24,
37, 50, 58, 65, 66). Different epitopes are exposed on oligo-
meric (gp140 or gp160) forms of Env compared to monomeric
Env (gp120) (12, 41, 58). In addition, the ability of anti-Env
antibodies to neutralize HIV-1 is predicted by binding to oli-
gomeric but not monomeric forms of Env (9, 67). The intrinsic
high background levels for HIV-1 neutralization assays in
mouse sera may have contributed to the poor neutralization
titers. The preimmune sera from these mice had anti-Env titers
of 1:20 to 1:40 that were deducted from each of the postim-
mune serum titers. Additional vaccine studies with sgp120
fused to the human homologue of C3d were performed in
rabbits, which do not show as high a background level in
preimmune sera. Rabbits primed with DNA and boosted with
protein or DNA showed higher neutralizing titers than did our
mouse study.
The correlation between avidity maturation and neutralizing
antibody production to gp120 has not always been clear. Some
studies have indicated a good correlation (18, 32, 33), whereas
others have not (16, 35). Future studies should be imple-
mented with Env immunogens that can elicit cross-clade, neu-
tralizing antibodies (9, 49, 57, 67), and therefore these titers
can then be raised by coupling to C3d. In addition, future
studies can explore the use of recombinant viral vectors (e.g.,
modified vaccinia virus Ankara [1, 3, 21, 25, 44, 45]), adenovi-
rus 5 (15), or alphavirus (13, 64), which are being used in many
preclinical AIDS vaccine studies. The introduction of C3d
fused immunogens into these viral vectors could be a more
effective strategy for enhancing immune responses.
One of the problems faced by those attempting to create an
HIV/AIDS vaccine is the ability to protect against the diversity
of isolates present in patient populations. A central goal has
been to identify immunogens capable of raising high-titer,
long-lasting, neutralizing antibody to the envelope glycopro-
teins of primary isolates. Our results presented in this study
suggest that, once a suitable Env immunogen is identified for
cross-reactive neutralizing antibody induction, C3d fusions
might be helpful as a molecular adjuvant to enhance antibody
production. If this can be accomplished, C3d fusions could
have a major impact on the development of the neutralizing
component for an AIDS vaccine. In addition, these results
underscore the importance of increasing our understanding of
the relationship between innate and acquired immunity. The
use of C3d as a vaccine adjuvant has great potential for a
variety of antigens, not only for infectious disease, including
biodefense agents, but also for nonimmunogenic self-proteins.
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